[A multicenter clinical study on clinical effects of meglumine cyclic adenylate in treating patients with chronic pulmonary heart disease].
To observe the clinical effects of meglumine cyclic adenylate (MCA) in treating patients with chronic pulmonary heart disease. 785 patients with chronic pulmonary heart disease were divided into two groups: MCA group and control group. Both groups of patients were treated with the same ordinary methods, but MCA was given in the MCA group. The period of treatment was 5-7 days. The degree of improvement in clinical symptoms, signs, ECG, pulmonary ventilation function and arterial blood gas analysis of the two groups before and after treatment were compared. The rates of improvement in clinical symptoms and signs were 92.2% and 73.6% in MCA group and control group respectively. VC increased (426 +/- 123) ml and (313 +/- 145) ml respectively as compared with the values before the treatment. FEV(1) increased (134 +/- 54) ml and (95 +/- 55) ml, PEF increased (0.78 +/- 0.32) L/s and (0.47 +/- 0.32) L/s and PaO(2) increased (23.4 +/- 9.5) mm Hg and (17.3 +/- 10.4) mm Hg respectively. The rates of ECG improvement were 63.7% and 41.2% respectively. There was significant difference between the two groups (P < 0.01 and 0.05). Significant therapeutic effects were obtained in treating patients of chronic pulmonary heart disease with respiratory and cardiac failure by using ordinary treatment measures combined with MCA injection.